Celgene (CELG) Revlimid Estimates, PT Lifted at Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- S&P 500 ends marginally lower as investors focus on US-Iran war
Celgene (CELG) Added to BofA/Merrill Lynch US 1 List
October 28, 2014 7:51 AM EDTBofA/Merrill Lynch added Celgene (NASDAQ: CELG) to its US 1 List while maintaining a Buy rating and price target of $112.00.
Analyst Ying Huang notes CELG is one of the highest growth companies among the large-cap biotechs and they expect compounded annual... More
Celgene (CELG) Price Target Raised to $134 at Deutsche Bank
October 24, 2014 9:07 AM EDTDeutsche Bank maintained a Buy rating on Celgene (NASDAQ: CELG) and raised its price target to $134.00 (from $115.00). Analyst Robyn Karnauskas said Celgene was emerging as top pick for 2015.
"The focus of the 3Q call was the strong Otezla launch, and the pipeline,... More
Celgene (CELG) Tops Q3 EPS by 2c
October 23, 2014 7:39 AM EDTCelgene (NASDAQ: CELG) reported Q3 EPS of $0.97, $0.02 better than the analyst estimate of $0.95. Revenue for the quarter came in at $1.96 billion versus the consensus estimate of $1.96 billion.
Net Product Sales Performance
REVLIMID® sales for the third quarter increased 19 percent to $1,300 million and were driven by volume in both the U.S. and International markets as a result of increased duration of therapy and continued market share leadership in multiple myeloma. U.S. sales of... More